Recent Company News

• 10:34 AM ET Oct 13, 2026
  

  EU chemicals trade defence opens 2027 catalyst window amid temporary war-related relief:

• 04:04 PM ET Oct 12, 2026
  

  Cytokinetics announces additional data from ACACIA-HCM presented at the HFSA Annual Scientific Meeting 2026 ($62.79, 0.00)

• 03:38 PM ET Oct 11, 2026
  

  BridgeBio Pharma reports Phase 3 ATTRibute-CM sub-analyses of acoramidis in ATTR-CM presented at HFSA ($65.35, 0.00)

• 02:31 AM ET Oct 08, 2026
  

  US FDA accepts Bayer's supplemental NDA for KERENDIA (finerenone) to treat adults with chronic kidney disease (CKD) without diabetes (€43.97, 0.00)

• 09:23 AM ET Oct 06, 2026
  

  Mint Pharmaceuticals (private) expands distribution agreement in Canada with Bayer (€44.72, +0.76)

• 11:18 AM ET Oct 05, 2026
  

  Zydus Lifesciences announces launch of Riociguat Tablets in US (INR 1138.50, 0.00)

• 02:46 AM ET Oct 05, 2026
  

  StreetAccount Summary - European pre-market trading update

• 03:15 PM ET Oct 02, 2026
  

  Bayer AG to invest $2.2B in new manufacturing site in New Albany, Ohio (€44.94, 0.00)

• 07:35 AM ET Sep 30, 2026
  

  Cytokinetics launches ASPEN-HCM: a real-world study evaluating MYQORZO (aficamten) in symptomatic obstructive hypertrophic cardiomyopathy ($65.64, 0.00)

• 10:33 AM ET Sep 28, 2026
  

  StreetAccount M&A Summary: Week of 21-Sep